We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+11.77%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$894M
AUM Growth
-$76.8M
Cap. Flow
-$55.1M
Cap. Flow %
-6.17%
Top 10 Hldgs %
76.13%
Holding
32
New
–
Increased
2
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
SVRA icon
Savara
SVRA
+$9.31M
2
TNGX icon
Tango Therapeutics
TNGX
+$5.92M

Top Sells

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$21.2M
2
DVAX
Dynavax Technologies
DVAX
+$21.1M
3
CBAY
Cymabay Therapeutics
CBAY
+$21M
4
THRD
Third Harmonic Bio
THRD
+$3.08M
5
TVRD
Tvardi Therapeutics
TVRD
+$2.37M

Sector Composition

Rank Sector Weight
1 Healthcare 98.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$164M 18.39%
3,577,267
– –
PHVS icon
2
Pharvaris
PHVS
$2.43B
$99.9M 11.17%
4,784,674
-84,110
-2% -$1.55M
NAMS icon
3
NewAmsterdam Pharma
NAMS
$3.34B
$96.9M 10.83%
10,473,913
– –
SWTX
4
DELISTED
SpringWorks Therapeutics
SWTX
$71.2M 7.97%
3,081,307
– –
IRON icon
5
Disc Medicine
IRON
$3.01B
$62.6M 7%
1,332,545
-3
-0% -$150
SVRA icon
6
Savara
SVRA
$1.17B
$53.8M 6.02%
14,232,751
+2,610,153
+22% +$9.31M
CRNX icon
7
Crinetics Pharmaceuticals
CRNX
$8.93B
$37.9M 4.24%
1,275,552
-1,030,006
-45% -$21.2M
TNGX icon
8
Tango Therapeutics
TNGX
$4.51B
$32.6M 3.64%
2,892,663
+970,873
+51% +$5.92M
NTRA icon
9
Natera
NTRA
$45.9B
$31M 3.46%
700,197
– –
CABA icon
10
Cabaletta Bio
CABA
$457M
$30.4M 3.4%
2,000,000
– –
ACRS icon
11
Aclaris Therapeutics
ACRS
$867M
$23.3M 2.6%
3,400,000
– –
EQRX
12
DELISTED
EQRx, Inc. Common Stock
EQRX
$22.2M 2.48%
10,003,573
– –
XFOR icon
13
X4 Pharmaceuticals
XFOR
$421M
$17.4M 1.95%
532,020
– –
ARQT icon
14
Arcutis Biotherapeutics
ARQT
$3.26B
$15.9M 1.78%
3,000,000
– –
NRIX icon
15
Nurix Therapeutics
NRIX
$2.69B
$14.3M 1.6%
1,822,883
– –
CBAY
16
DELISTED
Cymabay Therapeutics
CBAY
$13.6M 1.52%
913,969
-1,586,031
-63% -$21M
DVAX
17
DELISTED
Dynavax Technologies
DVAX
$13.5M 1.51%
915,000
-1,500,000
-62% -$21.1M
ANNX icon
18
Annexon
ANNX
$883M
$13.5M 1.5%
5,701,926
– –
MRNS
19
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$11.5M 1.29%
1,431,058
– –
MRSN
20
DELISTED
Mersana Therapeutics
MRSN
$11M 1.23%
346,547
– –
RPID icon
21
Rapid Micro Biosystems
RPID
$85.2M
$9.11M 1.02%
8,434,560
– –
SYRS
22
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$8.39M 0.94%
2,124,694
– –
SLDB icon
23
Solid Biosciences
SLDB
$918M
$7.89M 0.88%
3,130,422
– –
AVIR icon
24
Atea Pharmaceuticals
AVIR
$402M
$7.46M 0.83%
2,485,638
– –
NAUT icon
25
Nautilus Biotechnolgy
NAUT
$110M
$6.32M 0.71%
2,000,000
– –
1
2

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q3 2023 Portfolio in Review

As of Q3 2023, Bain Capital Life Sciences Investors held 32 positions worth $894M, down 7.9% from $971M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Bain Capital Life Sciences Investors withdrew a net $55.1M in Q3 2023, closing 1 position and reducing 6 holdings. Its most notable exit was Third Harmonic Bio, an estimated $3.08M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier.

Against the trend, Bain Capital Life Sciences Investors added an estimated $9.31M to Savara.

  • Bain Capital Life Sciences Investors added most to Savara in Q3 2023, an estimated $9.31M increase.
  • Bain Capital Life Sciences Investors's biggest Q3 2023 reduction was Crinetics Pharmaceuticals, cutting an estimated $21.2M.
  • Bain Capital Life Sciences Investors fully exited Third Harmonic Bio in Q3 2023, selling an estimated $3.08M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 76% of its $894M portfolio in Q3 2023.
  • Bain Capital Life Sciences Investors opened 0 new positions and closed 1 in Q3 2023.
  • Bain Capital Life Sciences Investors's portfolio value fell 7.9% quarter-over-quarter to $894M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q3 2023, filed 14 Nov 2023.